MediRedox: Global Leader in APE1/Ref-1 Innovation

At MediRedox, our core technology is built upon decades of pioneering research into APE1/Ref-1 (Apurinic/apyrimidinic endonuclease 1/redox factor-1). Our proprietary detection methods and therapeutic strategies are rigorously validated by high-impact, peer-reviewed publications.

Explore the key scientific evidence driving our mission to transform diagnostics and treatments for intractable cancers, inflammatory, and metabolic diseases.

1. Breakthroughs in Intractable & Refractory Cancers

• Overcoming Chemoresistance: Leveraging the secretable and redox functions of APE1/Ref-1 to induce apoptosis in the most challenging malignancies.

• Synergistic Therapies: Demonstrating the powerful synergistic effects of combining acetylsalicylic acid with recombinant human APE1/Ref-1 to target chemo-resistant models, including triple-negative breast cancer (TNBC) and ovarian cancer.

2. Clinical Diagnostics & Biomarker Validation

• Robust Biomarkers: Pioneering the clinical utility of plasma/serum APE1/Ref-1 levels to detect malignancies, monitor disease progression, and predict clinical outcomes.

• Precision Care: Tracking fluctuations in APE1/Ref-1 expression during surgical interventions to identify treatment-refractory cases and guide precision diagnostics.

3. Severe Inflammation & Organ Protection

• Vital Organ Defense: Uncovering the critical protective role of APE1/Ref-1 against systemic inflammation, oxidative stress, and fibrosis.

• Mitigating Toxicity: Demonstrating how secretory APE1/Ref-1 suppresses ROS pathways to prevent drug-induced toxicities (e.g., cardiotoxicity) and halts pathological shifts in vascular and renal systems via redox-dependent mechanisms.

Since our founding in 2018, this extensive body of research has served as the ultimate validation of our precision and reliability. Our publications form the foundation of our commitment to scientific excellence—bridging the gap between advanced molecular discoveries and life-saving patient care.